Drug updated on 3/28/2024
| Dosage Form | Tablet (oral; 90 mg) |
| Drug Class | Substance P/neurokinin 1 (NK1) receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Summary
- Rolapitant (Varubi) is used in combination with other antiemetic agents for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
- In adults receiving highly or moderately emetogenic chemotherapy, rolapitant combined with 5-HT₃ receptor antagonists and corticosteroids may be less effective than aprepitant plus granisetron in controlling vomiting during the overall treatment phase according to a systematic review/meta-analysis.
- The same study found that fewer participants might experience serious adverse events when treated with rolapitant plus granisetron compared to aprepitant plus granisetron, suggesting a potential safety advantage for rolapitant.
- Another meta-analysis indicated that adding neurokinin-1 receptor antagonist like rolapitant to dexamethasone and 5-HT3RA significantly improves complete response rates in patients undergoing carboplatin-based chemotherapy, highlighting its effectiveness against chemo-induced nausea/vomiting.
- A separate analysis concluded that olanzapine-based triple regimens were superior in both overall and delayed-phase nausea control compared to various neurokinin-1 receptor antagonists including rolapitant based triple regimens among patients receiving highly emetogenic chemotherapy; however, no significant difference was observed regarding complete responses between these two types of regimen.
- These findings are based on five systematic reviews/meta-analyses, incorporating data from numerous randomized controlled trials. These trials involved thousands of adult cancer patients undergoing various types of chemotherapy treatments across multiple geographical regions worldwide.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Varubi (rolapitant) Prescribing Information. | 2020 | FDA |